INTRODUCTION: In recent decades, a steady improvement in imaging diagnostics has been observed together with a rising adherence to regular clinical breast examinations. As a result, the detection of small clinically occult (nonpalpable) lesions has progressively increased. At present in our institution some 20% of the cases are treated when nonpalpable. The aim of the present study is to analyze the characteristics and prognosis of such tumors treated in a single institution. METHODS: The analysis focused on 1,258 women who presented at the European Institute of Oncology with a primary clinically occult carcinoma between 2000 and 2006. All patients underwent radioguided occult lesion localization (ROLL), axillary dissection when appropriate, whole breast radiotherapy, or partial breast intraoperative irradiation and received tailored adjuvant systemic treatment. RESULTS: Median age was 56 years. Imaging showed a breast nodule in half of the cases and a breast nodule accompanied by microcalcifications in 9%. Microcalcifications alone were present in 17.1% of the cases, whereas suspicious opacity, distortion, or thickening represented the remaining 24.6%. Most tumors were characterized by low proliferative rates (68.9%), positive estrogen receptors (92.3%), and non-overexpressed Her2/neu (91.3%). After a median follow-up of 60 months, we observed 19 local events (1.5%), 12 regional events (1%), and 20 distant metastases (1.6%). Five-year overall survival was 98.6%. CONCLUSIONS: Clinically occult (nonpalpable) carcinomas show very favorable prognostic features and high survival rates, showing the important role of modern imaging techniques.
INTRODUCTION: In recent decades, a steady improvement in imaging diagnostics has been observed together with a rising adherence to regular clinical breast examinations. As a result, the detection of small clinically occult (nonpalpable) lesions has progressively increased. At present in our institution some 20% of the cases are treated when nonpalpable. The aim of the present study is to analyze the characteristics and prognosis of such tumors treated in a single institution. METHODS: The analysis focused on 1,258 women who presented at the European Institute of Oncology with a primary clinically occult carcinoma between 2000 and 2006. All patients underwent radioguided occult lesion localization (ROLL), axillary dissection when appropriate, whole breast radiotherapy, or partial breast intraoperative irradiation and received tailored adjuvant systemic treatment. RESULTS: Median age was 56 years. Imaging showed a breast nodule in half of the cases and a breast nodule accompanied by microcalcifications in 9%. Microcalcifications alone were present in 17.1% of the cases, whereas suspicious opacity, distortion, or thickening represented the remaining 24.6%. Most tumors were characterized by low proliferative rates (68.9%), positive estrogen receptors (92.3%), and non-overexpressed Her2/neu (91.3%). After a median follow-up of 60 months, we observed 19 local events (1.5%), 12 regional events (1%), and 20 distant metastases (1.6%). Five-year overall survival was 98.6%. CONCLUSIONS: Clinically occult (nonpalpable) carcinomas show very favorable prognostic features and high survival rates, showing the important role of modern imaging techniques.
Authors: A Luini; S Zurrida; G Paganelli; V Galimberti; V Sacchini; S Monti; P Veronesi; G Viale; U Veronesi Journal: Br J Surg Date: 1999-04 Impact factor: 6.939
Authors: Umberto Veronesi; Giovanni Paganelli; Giuseppe Viale; Alberto Luini; Stefano Zurrida; Viviana Galimberti; Mattia Intra; Paolo Veronesi; Patrick Maisonneuve; Giovanna Gatti; Giovanni Mazzarol; Concetta De Cicco; Gianfranco Manfredi; Julia Rodríguez Fernández Journal: Lancet Oncol Date: 2006-12 Impact factor: 41.316
Authors: Laszlo Tabar; Ming-Fang Yen; Bedrich Vitak; Hsiu-Hsi Tony Chen; Robert A Smith; Stephen W Duffy Journal: Lancet Date: 2003-04-26 Impact factor: 79.321
Authors: C De Cicco; M Pizzamiglio; G Trifirò; A Luini; M Ferrari; G Prisco; V Galimberti; E Cassano; G Viale; M Intra; P Veronesi; G Paganelli Journal: Q J Nucl Med Date: 2002-06
Authors: Umberto Veronesi; Viviana Galimberti; Giovanni Paganelli; Patrick Maisonneuve; Giuseppe Viale; Roberto Orecchia; Alberto Luini; Mattia Intra; Paolo Veronesi; Pietro Caldarella; Giuseppe Renne; Nicole Rotmensz; Claudia Sangalli; Luciana De Brito Lima; Marco Tullii; Stefano Zurrida Journal: Eur J Cancer Date: 2009-01-06 Impact factor: 9.162
Authors: Nidal İflazoğlu; Orhan Üreyen; Murat Kemal Atahan; Ulvi Mehmet Meral; Gülten Sezgin; Ercüment Tarcan Journal: J Breast Health Date: 2015-07-01
Authors: Laura G Merckel; Helena M Verkooijen; Nicky H G M Peters; Ritse M Mann; Wouter B Veldhuis; Remmert K Storm; Teun Weits; Katya M Duvivier; Thijs van Dalen; Willem P Th M Mali; Petra H M Peeters; Maurice A A J van den Bosch Journal: PLoS One Date: 2014-04-08 Impact factor: 3.240
Authors: Michela Franchini; Stefania Pieroni; Edgardo Montrucchio; Jacopo Nori Cucchiari; Cosimo Di Maggio; Enrico Cassano; Brunella Di Nubila; Gian Marco Giuseppetti; Alberto Nicolucci; Gianfranco Scaperrotta; Paolo Belli; Sonia Santicchia; Sabrina Molinaro Journal: Int J Environ Res Public Health Date: 2021-03-02 Impact factor: 3.390